Eli Lilly & Co. is the latest company to join the new trend of offering the same drug in two different versions to get around obstacles in the health care system that keep some patients from benefiting from rebates. The company announced March 4 that it will launch an authorized generic version of its short-acting insulin Humalog in the US at a 50% discount to the list price of the brand.
The authorized generic will be called Insulin Lispro – the generic name for the molecule – and will be available...





